Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9280470 | 0.94 | TDP1 (0.44) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL16117975 | 0.87 | LMNA (0.46) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL16117976 | 0.84 | LMNA (0.47) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL28083185 | 0.82 | ALDH1A1 (0.48) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL2595478 | 0.82 | SMN1; SMN2 (0.41) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL10983166 | 0.81 | LMNA (0.51) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL5208330 | 0.81 | TDP1 (0.44) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL16093606 | 0.81 | LMNA (0.41) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL8536622 | 0.80 | MERTK (0.51) | TDP1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL31188768 | 0.80 | LMNA (0.54) | TDP1LMNAALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| CN-105189456-B | Covalent inhibitors of KRAS G12C | 亚瑞克西斯制药公司 | 2017-12-19 | — | — | CN | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-2970121-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | TDP1 2744/4885LMNA 3439/4885ALDH1A1 2706/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | TDP1 2744/4885LMNA 3439/4885ALDH1A1 2706/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | TDP1 2744/4885LMNA 3439/4885ALDH1A1 2706/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | TDP1 1694/4885LMNA 3223/4885ALDH1A1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.